We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Study of Elacytarabine Versus Investigator's Choice in Patients With Late Stage Acute Myeloid Leukaemia (AML) (CLAVELA)

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT01147939
First Posted: June 22, 2010
Last Update Posted: September 27, 2013
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Clavis Pharma
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been completed.
  Study Completion Date: June 2013
  Primary Completion Date: February 2013 (Final data collection date for primary outcome measure)
  Certification or Request for Extension to Delay Results Submission: September 12, 2013
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):